Preetika Rana is an award-winning reporter for The Wall Street Journal in San Francisco with experience reporting from six ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, ...

Beth Marsh will lead commercialization for Neurotech, which gained FDA approval for its eye disease therapy. Neurotech in May ...

The Irish arm of pharma firm, Takeda, last year sustained a €37.2m hit to profits after mothballing new manufacturing ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Net product revenues have likely increased in the first quarter, driven by a rise in Cabometyx sales volumes and average net selling price. Cabometyx is approved for advanced renal cell carcinoma (RCC ...

Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Recursion Pharmaceuticals, Inc.’s RXRX share price has surged by 7.02%, which has investors questioning if this is right time ...

Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.